The Company acknowledges the Staff’s comment and respectfully advises the Staff that, with respect to potential indirect consequences of climate change on our financial conditions and results of operations, we considered whether any the following have had a material impact:
a)decreased demand for goods or services that produce significant greenhouse gas emissions or are related to carbon-based energy sources;
b)increased demand for goods that result in lower emissions than competing products;
c)increased competition to develop innovative new products that result in lower emissions; and
Rest of the answer
d)any anticipated climate-related reputational risks resulting from operations or products that we sell.
As further discussed below, based on the nature of our operations as a global biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, we have not identified potential direct or indirect consequences of climate change that have had or would have a material effect on our financial condition or results of operations. However, we are committed to reducing our carbon emissions as reported in our annual ESG Report and will continue to monitor for future indirect consequences and will disclose relevant information, if material. To this end, early this year, we hired a Senior Director, Global Reputation and ESG Lead to help us develop and implement a global ESG strategy including a climate action plan. Additionally, in 2022, we plan to engage a third-party consulting firm to, among other things:
•Measure and analyze BeiGene’s global Scope 1 and 2 energy, greenhouse gas emissions, water, waste, and packaging footprint from offices, distribution centers, research and development laboratories, and manufacturing facilities for fiscal year 2022, which will establish a baseline year for the Company’s global emissions and footprint;
•Conduct an assessment of Scope 3 emissions to determine areas of material emissions and inform future efforts on reducing greenhouse gas emissions and footprint;
•Develop a comprehensive global carbon reduction strategy, including forward-looking targets; and
•Assess climate-related risks and opportunities using the TCFD framework.
We will provide the result of these assessments in our future annual ESG Reports. To the extent any of the assessments are material to an understanding of the Company’s business, financial condition or results of operations, we will include relevant disclosure in our future SEC filings.
Decreased demand for goods or services that produce significant greenhouse gas emissions or are related to carbon-based energy sources
Annual disclosure of our Scope 1 and Scope 2 GHG emissions for certain facilities, as well as other related data, can be found in our annual ESG Report. Our 2018 data covers major operations in China, including our Beijing laboratory, Beijing office building, Suzhou factory and Suzhou office building for the period from January 1, 2018 to December 31, 2018. Other small offices in China, overseas offices and facilities under construction are not included. Our 2019 ESG Report covers the major operations of BeiGene, including our Beijing R&D center, Suzhou and Guangzhou plants, all office buildings located in China and an office in the United States for the period from January 1, 2019 to December 31, 2019. Our 2020 ESG Report covers the major operations of BeiGene, including our Beijing and Shanghai R&D centers, Suzhou and Guangzhou manufacturing facilities, all office buildings located in China, and the Cambridge office in the United States for the period from January 1, 2020 to December 31, 2020.
As we noted in our response to comment 1, our manufacturing processes require that we purchase significant quantities of energy from third parties, which results in the generation of greenhouse gases. During the year ended December 31, 2019 and December 31, 2020, the Company spent approximately $[****] and $[****], respectively, on energy sources. Additionally, our manufacturing processes also result in greenhouse gas emissions from certain chemical reactions necessary to manufacture our clinical-stage and commercial drug products as well as the handling of waste. During the year ended December 31, 2019 and December 31, 2020, the Company spent approximately $[****] and $[****], respectively, on the handling of waste and hazardous materials. The Company does not consider these costs material.
With respect to transportation, goods and services that produce significant greenhouse gas emissions or those related to carbon-based energy sources primarily come from burning fossil fuel for vehicles we rent and use commercially. During the year ended December 31, 2019 and December 31, 2020, the Company spent approximately $[****] and $[****], respectively, on rental vehicles, which the Company does not consider material.
Given the nature of our operations, any decreased demand for goods or services that produce significant greenhouse gas emissions resulting from any effect of carbon pricing, diesel and petrol vehicle restrictions, and higher costs of energy have not had any material impact on the Company, as discussed above.
Increased demand for goods that result in lower emissions than competing products
Given the nature of our operations as a global biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, the increased demand for goods that result in lower emissions than competing products have not had any material impact on the Company and will not be material for fiscal years 2021 and 2022, respectively. As disclosed in our 2020 ESG Report, the Company has been investing in energy management projects, which cut operating costs and contribution to global energy reduction. As noted in our response letter dated October 29, 2021, during the year ended December 31, 2019 and December 31, 2020, the Company incurred approximately $[****] and $[****] on capital expenditures for climate-related projects. We estimate that our capital expenditures for climate-related projects will be approximately $[****] and $[****] and not be material for fiscal years 2021 and 2022, respectively.
Additionally, during the year ended December 31, 2019 and December 31, 2020, the Company spent approximately $[****] and $[****], respectively, on electricity and steam, a portion of which include renewal energy. Similarly, during the year ended December 31, 2019 and December 31, 2020, the Company spent approximately $[****] and $[****], respectively, on handling waste. Further, the Company estimates that it will spend approximately $[****] and $[****] on its recycling policy in fiscal years 2021 and 2022, respectively. The Company does not consider these costs material.
Increased competition to develop innovative new products that result in lower emissions
Based on the nature of our operations as a global biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, we have not experienced any increased competition to develop innovative new products that result in lower emissions. Our research organization has delivered ten molecules into the clinic in our first ten years, including our two lead commercial medicines, BRUKINSA®, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers, and tislelizumab, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers. We have received regulatory approvals to market BRUKINSA® in the world’s three largest pharmaceutical markets, the United States, China and the European Union, and tislelizumab in China, with an established, science-based commercial organization.
We have built state-of-the-art biologic and small molecule manufacturing facilities in China to support the potential future demand of our products, and we also work with high quality contract manufacturing organizations to manufacture our internally developed clinical and commercial products. We follow strict quality control standards in testing, manufacturing, packaging, storage, and distribution of our medicines and are committed to maintaining high standards on safety and product quality. Our research laboratories and manufacturing facilities are currently located solely in China, with our operations in the United States, Europe, Australia and other locations around the world conducted from rented, commercially available office space. However, we recently announced that we have acquired a 42-acre site at the Princeton West Innovation Campus in Hopewell, N.J. and plan to build a new state-of-the-art manufacturing campus and clinical R&D center there.
Any anticipated climate-related reputational risks resulting from operations or products that we sell
Since 2018, we have conducted an annual materiality assessment to identify the ESG issues most important to our stakeholders and business. These assessments are reviewed annually and published in our 2018 annual report as well as our 2019 and 2020 ESG reports, including disclosure of our energy use, greenhouse gas emissions, water consumption, waste, and packaging use across some of our sites. Our 2018 data covers major operations in China, including our Beijing laboratory, Beijing office building, Suzhou factory and Suzhou office building for the period from January 1, 2018 to December 31, 2018. Other small offices in China, overseas offices and facilities under construction are not included. Our 2019 ESG Report covers the major operations of BeiGene, including our Beijing R&D center, Suzhou and Guangzhou plants, all office buildings located in China and an office in the United States for the period from January 1, 2019 to December 31, 2019. Our 2020 ESG Report covers the major operations of BeiGene, including our Beijing and Shanghai R&D centers, Suzhou and Guangzhou manufacturing facilities, all office buildings located in China, and the Cambridge office in the United States for the period from January 1, 2020 to December 31, 2020. We expect to report Scope 1 and 2 GHG emissions as well as water consumption, waste and packaging use for all of our facilities in our 2021 ESG Report.
To date, we have not observed any impact on the Company’s reputation from this publicly available data nor based on our results of operations and product revenue as discussed in the Company’s annual report on Form 10-K and quarterly reports on Form 10-Q. Additionally, our stock price has steadily increased from $100.81 per share on January 2, 2018 to $314.14 per share on December 4, 2021.
We began generating product revenue in September 2017 through our in-license agreement with BMS to distribute the approved cancer therapies REVLIMID®, VIDAZA®, and ABRAXANE® in China. Following approval from the FDA in November 2019, we launched our first internally developed medicine, BRUKINSA®, in the United States. We launched our second internally developed medicine, tislelizumab, in China in March 2020 and in June 2020, we launched BRUKINSA® in China. We currently have 12 internally developed and in-licensed medicines that are approved for use in China. With our first approval in the European Union in November 2021, BRUKINSA is now approved in the United States, China, the European Union and nine other countries and regions.